Profile number 103319
Production of Medical Cannabis
17/01/2022 Date added
Located in
Germany
General information
Sector
Healthcare
Type of company
Other
Legal entity
Foreign legal entity
Type of transaction
Shares
Life phase enterprise
Growing
Employees in FTE
5 - 10
Type of buyer
Investor
Financial information
Turnover last financial year
Confidential
Asking price
€ 500.000 - € 1.000.000
Earnings before taxes
Confidential
Company history/background
- Company history / background
The company supplys patients with high quality medical cannabis. The goal is to guarantee a reliable supply at a competitive price. They will increase the production capacity in phases and are prepared to enter new markets in the expanding European cannabis industry. The company is based in Germany. The cultivation facilities are located in Portugal because of the low labour cost, the perfect climate and the taks incentives.
The cannabis plant has been used all over the world for millennia in patient care. It's over 600 compounds include many cannabinoids and terpenes that are used to treat various diseases. Grow MDCL will produce cannabis flowers of the sativa and indica subspecies of the female plant Cannabis sativa L. for the production of medical cannabis.
Company activities
- Investor
The emerging European Cannabis market presents a great opportunity for young companies and for investors to be a part of an entirely new branch of business with enormous potential. The stigma attached to medicinal cannabis is fading away quickly, the benefits of the cannabis plant are becoming more obvious to patients, politicians and scientists.
We are seeking partners who share our vision of supplying medical cannabis to a steadily growing number of patients in Germany and Europe.
- Investment
The company want's to rais € 1.000k for facility construction Probably a 2nd investment will be necessary in Q2 2022 for market growth and expansion.
Begin cultivation January 2021, sales of first flower product April 2022..
The result is expected to be break even in augustus 2022.. Budgeted turnover indication for 2022 € 4 million
Unique selling points
- Own Cultivation
Identified as key risk and differentiating factor - the cornerstone of our EU market strategy - adapting to maturing market
- Own Brand
Reserved for premium cultivars and premium flower - building brand value in preparation for legalisation
- Whitelabel growing
Maximising potential of facility - generate highest revenue and returns
- Formulations & Delivery
In partnership with existing extractors and delivery technology providers
- The Team
The company works with a highly motivated team with medical, financial, regulatory and operational experience that works with their local partners and the Portuguese authorities. The three founders are taking hands-on management roles in the company and will be acting as Director of Finance, Medical Director and Director of Operations.
Other
- company activities
All our products are manufactured under valid licenses, according to industry standards and are subject to constant quality controls.
- Cultivation
The products are grown in a modern and efficient cultivation facility in Portugal. The experienced Master Grower has a long track record of successfully producing high quality medical cannabis flowers. We expect to finalise licensing procedures in Q3 of 2021 and start cultivation in Q4 of 2021.
The keywords ars:
- Quality
- Consistency
- Competitiveness
- Growth
VISION: To integrate European supply into the global cannabis market - founded on medical - prepared for recreational
MISSION: By controlling our own supply, create a top-end brand of medical and recreational cannabis in Europe
Production of Medical Cannabis
Region
Germany
Sector
Healthcare
Type
For sale
Turnover
Confidential
Overname
500.000 - 1.000.000